Grifols SA (G0FB) AI Stock Analysis

Grifols SA

(Frankfurt:G0FB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Immunoglobulin growthStrong immunoglobulin growth indicates sustained demand for Grifols’ core plasma-derived therapies, particularly subcutaneous products. Continued adoption can support revenue mix, manufacturing scale, and operating leverage over the next several quarters while reinforcing the company’s position in chronic-care treatment markets.

Negative Factors

High leverageHigh leverage remains a durable constraint on financial flexibility despite some improvement from 2023 levels. Debt service and refinancing needs can absorb cash that might otherwise support growth or deleveraging, while elevated leverage leaves Grifols more exposed to operational setbacks and weaker earnings.

Grifols SA (G0FB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.85B
Dividend Yield: 3.37%
Average Volume (3M): ―
Price to Earnings (P/E): 16.4
Beta (1Y): 0.54
Revenue Growth: -0.33%
EPS Growth: 51.93%
Country: Germany
Employees: 25,258
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Grifols SA Business Overview & Revenue Model

Company Description

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organiz...

Grifols SA Earnings Call Summary

Earnings Call Date:Jul 27, 2026(Q2-2026)|% Change Since:6.06%|Next Earnings Date:Nov 01, 2026

Earnings Call SentimentPositive

Overall the call conveys a constructive and confident tone: the company reported modest top-line growth with strong momentum in Biopharma—notably IG and subcutaneous IG—improving adjusted EBITDA, higher group profit, and better free cash flow. Strategic initiatives (Egypt plasma ramp, diagnostics platform development, Biopharma reorganization, Biotest turnaround) and debt refinancing strengthen the long‑term profile. Near-term headwinds include albumin pricing effects in China, one‑off costs from donor center closures, and transitional diagnostics comparability, but management provided clear mitigation plans and timing for expected benefits.

Positive Updates

Solid First-Half Revenue Growth

Group revenue for H1 2026 reached €3.574 billion, up 2.6% at constant currency, with Biopharma driving growth (Biopharma +5.4% at constant currency).

Negative Updates

Albumin Headwinds in China

Albumin faced year-on-year pricing impact in China following a mid‑2025 price adjustment; Q2 had a particularly challenging comparison due to post-license renewal catch-up. Management expects stabilization in H2 but headwinds affected H1 performance.

Company Guidance

The company reiterated full‑year 2026 guidance while highlighting a strong H1: group revenues of €3.574bn (up 2.6% cc) with Q2 revenues €1.874bn; Biopharma +5.4% cc (IG +12.8% cc) and XEMBIFY accelerating with strong double‑digit growth; adjusted EBITDA of €472m in Q2 (25.2% margin) and €854m in H1 (≈23.9% margin); reported gross margin 37.6% in Q2 / 37.1% H1 (excluding one‑offs 39.4% Q2 / 38.6% H1); H1 group profit $227m (+28.7% YoY) and free cash flow before M&A €91m (+€103m YoY) with full‑year FCF guidance €500–575m; one‑offs include €40m (≈€25m non‑cash) for closing 29 U.S. donation centers; balance sheet: total net leverage ~4.2x, net secured 2.7x, liquidity ~$2bn; albumin expected to stabilize with H2 absolute levels in line with H2 last year; Egypt/ex‑U.S. plasma to ramp (≈25% of ex‑U.S. today, targeting ~50% by 2029 and ~1m collections in 2026 → ~3m by 2029); capital spend normalizing and cash interest expected broadly in line with 2025.

Grifols SA Risk Analysis

Grifols SA disclosed 53 risk factors in its most recent earnings report. Grifols SA reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Failure to comply with changing regulatory requirements could materially adversely affect our business.Q4, 2020

2.We rely on the services of third parties for the manufacture of certain products.Q4, 2020

3.Our business could suffer as a result of the United Kingdom's decision to end its membership in the European Union.Q4, 2020

Grifols SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:G0FB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMGN	75Outperform	$251.94B	28.73	89.32%	2.13%	9.89%	31.69%
ABBV	72Outperform	$521.11B	50.58	-223.75%	2.35%	10.68%	―
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
GSK	67Neutral	$99.56B	17.18	24.64%	3.67%	6.93%	-18.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:G0FB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:G0FB	Grifols SA	7.00	-0.85	-10.83%
AMGN	Amgen Inc	466.01	177.71	61.64%
GSK	GlaxoSmithKline	49.51	4.72	10.55%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
SNY	Sanofi SA	44.34	-3.79	-7.87%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Grifols SA AI Stock Analysis